References

Ahn, S., Woo, J., Lee, K., & Park, S. (2020). HER2 status in breast cancer: Changes in guidelines and complicating factors for interpretation. Journal of Pathology and Translational Medicine, 54: 34–44. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986968/pdf/jptm-2019-11-03.pdf

Anamika, F., Chitkara, A., Saharan, K., Choudhary, T., Soni, U., Harmon, G. A., & Saeed, A. (2023). Trastuzumab-induced cardiotoxicity in breast cancer patients: A meta-analysis and review of the literature (2012-2022). Journal of Clinical Oncology, 41(16_suppl), e24101. https://doi.org/10.1200/jco.2023.41.16_suppl.e24101

Breast cancer diagnostics. (n.d.). Roche Diagnostics. https://diagnostics.roche.com/global/en/products/product-category/health-topic/oncology/breast-cancer.html

CAP Commission on laboratory accreditation: Laboratory accreditation program. (2024). Anatomic Pathology Checklist. College of American Pathologists.

Chalasani, P. (2025). Breast Cancer: practice essentials, background, anatomy. Medscape. https://emedicine.medscape.com/article/1947145-overview#a1

College of American Pathologists. (2018). HER2 test guideline recommendations: Summary of guideline. https://documents.cap.org/documents/asco-cap-her2-recommendations.pdf

College of American Pathologists. (2023). HER2 testing in breast Cancer - 2023 Guideline update. https://www.cap.org/protocols-and-guidelines/cap-guidelines/current-cap-guidelines/recommendations-for-human-epidermal-growth-factor-2-testing-in-breast-cancer

HercepTest™ for Dako Autostainer. (2022). Agilent. https://www.agilent.com/cs/library/packageinsert/public/PD04084US_03.pdf

Invitrogen™ [package insert]. (2008). Invitrogen Corporation.

Koopman, T., Buikema, H. J., Hollema, H., de Bock, G. H., & van der Vegt, B. (2019). What is the added value of digital image analysis of HER2 immunohistochemistry in breast cancer in clinical practice? A study with multiple platforms. Histopathology, 74(6), 917–924. https://doi.org/10.1111/his.13812

Ménard, S., Tagliabue, E., Campiglio, M., & Pupa, S. M. (2000). Role of HER2 gene overexpression in breast carcinoma. Journal of cellular physiology, 182(2), 150–162. https://doi.org/10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E

Modi, S., et al. (2022). Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer. New England Journal of Medicine, 387(1), 9–20. https://doi.org/10.1056/nejmoa2203690

Omopariola, D. (2023). Herceptin and cost. Medical News Today. https://www.medicalnewstoday.com/articles/drugs-herceptin-cost

PathVysion. (2022). Abbott Molecular. http://www.abbottmolecular.com/us/products/oncology/fish/breast-cancer-pathvysion-her2.html

Tucatinib. (2020). National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/tucatinib

Wolff, A., Hammond, M., Hicks, D., Dowsett, M., & McShane L. (2013). Recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. http://jco.ascopubs.org/content/31/31/3997.full